Wei Yang

Wei Yang has extensive work experience in the field of biotechnology and medicine. Wei is currently serving as the Chief Scientific Officer (CSO) at GV20 Therapeutics since May 2021. Prior to this role, they were a Scientific Advisory Board (SAB) member at GO Therapeutics from February 2019 to February 2022 and at Hummingbird Bioscience from October 2018 to February 2022.

Wei Yang also held significant positions at the Institute for Protein Innovation, where they served as the Director of Target Discovery from March 2018 to May 2021 and acted as the Chief Operating Officer (COO) from April 2019 to December 2019. Before that, they were the Director of the Molecular Biology Department at Novo Nordisk from November 2006 to March 2018.

Wei'searlier work experience includes serving as an Instructor of Medicine at the Beth Israel Deaconess Medical Center, Harvard Medical School from September 2005 to November 2006 and as a Postdoctoral Research Fellow at the CBR Institute for Biomedical Research, Harvard Medical School from July 2001 to September 2005.

Wei Yang received a Bachelor of Science (B.S.) degree in Biochemistry from Jilin University in 1995. From 1995 to 1998, Wei pursued a Master of Science (M.S.) degree in Biochemistry, also at Jilin University. Subsequently, from 1998 to 2001, Wei completed a Doctor of Philosophy (Ph.D.) degree in Cell Biology at Peking University.